EXALENZ BIOSCIENCE LTD

Andere talen Exalenz Bioscience Ltd

Aandelen

EXEN

IL0011048688

Vertraagde tijd TEL AVIV STOCK EXCHANGE Andere beurzen			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
- ^ILa	-.--%		+1,39%	+107,88%

2018

Exalenz Bioscience Ltd rapporteert winstresultaten voor het vierde kwartaal en het volledige jaar eindigend op 31 december 2017; geeft winstrichtlijnen voor het jaar 2018 en omzetrichtlijnen voor het jaar 2019

CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Meridian Bioscience, Inc. completed the acquisition of Exalenz Bioscience Ltd from Mori Arkin and others.	30-04-20
Meridian Bioscience : Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform	19-02-20
Meridian Bioscience, Inc. agreed to acquire Exalenz Bioscience Ltd from Mori Arkin and others for approximately ILS 170 million.	19-02-20
Exalenz Bioscience Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2019	14-08-19
Exalenz Bioscience Receives Approval for Commercial Marketing in China for Its Breathid® HP Lab System	25-02-19
Exalenz Bioscience Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	15-11-18
Exalenz Bioscience Ltd Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2018	31-08-18
Exalenz Bioscience Ltd. Announces BreathID®13C-methacetin Breath Test	10-07-18
Exalenz Bioscience Appoints Roy Golan as President and Chief Financial Officer	30-04-18
Exalenz Bioscience’s BreathID® Hp & BreathID Hp Lab Systems Receive FDA Clearance for Diagnosis of Helicobacter pylori Testing in Pediatric Patients	13-03-18
Exalenz Bioscience Ltd Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017; Provides Earnings Guidance for the Year 2018 and Revenue Guidance for the Year 2019	12-03-18
Exalenz Bioscience Announces Positive Clinical Trial Results for the Diagnosis of Clinically Significant Portal Hypertension in NASH Patients	24-01-18
Exalenz Bioscience Ltd Launches Automated BreathID® Hp Lab Urea Breath Testing System For Helicobacter pylori Detection	17-08-17
Exalenz Bioscience Plans For Nasdaq IPO	14-08-17
Exalenz Bioscience Receives FDA Marketing Clearance for its Laboratory System in the United States	01-11-16
Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to Use BreathID to Monitor Patients with Cirrhosis Associated with NASH	03-08-15
Exalenz Bioscience Ltd and Galectin Therapeutics, Inc. Receive FDA Approval for Joint Clinical Trial of Second-Stage of GR-MD-02	02-08-15
Exalenz Bioscience Ltd Launches Clinical Study for Breath-Based Detection of Primary Liver Cancer	04-06-15
Exalenz Bioscience Launches Additional Clinical Study of Breath-Based Diagnostic Test	06-05-15
Exalenz Bioscience Ltd. Auditor Raises 'Going Concern' Doubt	26-02-15

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Alle transcripties over 9000 bedrijven, de dag van publicatie!

Krijg nu toegang!

fermer